DNTH Relative Valuation
DNTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DNTH is overvalued; if below, it's undervalued.
Historical Valuation
Dianthus Therapeutics Inc (DNTH) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.69. The fair price of Dianthus Therapeutics Inc (DNTH) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：45.02
Fair
-11.52
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Dianthus Therapeutics Inc. (DNTH) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-7.30
EV/EBIT
Dianthus Therapeutics Inc. (DNTH) has a current EV/EBIT of -7.30. The 5-year average EV/EBIT is -3.66. The thresholds are as follows: Strongly Undervalued below -7.77, Undervalued between -7.77 and -5.71, Fairly Valued between -1.60 and -5.71, Overvalued between -1.60 and 0.46, and Strongly Overvalued above 0.46. The current Forward EV/EBIT of -7.30 falls within the Undervalued range.
1865.30
PS
Dianthus Therapeutics Inc. (DNTH) has a current PS of 1865.30. The 5-year average PS is 392.69. The thresholds are as follows: Strongly Undervalued below -374.43, Undervalued between -374.43 and 9.13, Fairly Valued between 776.25 and 9.13, Overvalued between 776.25 and 1159.81, and Strongly Overvalued above 1159.81. The current Forward PS of 1865.30 falls within the Strongly Overvalued range.
-16.49
P/OCF
Dianthus Therapeutics Inc. (DNTH) has a current P/OCF of -16.49. The 5-year average P/OCF is -8.48. The thresholds are as follows: Strongly Undervalued below -16.34, Undervalued between -16.34 and -12.41, Fairly Valued between -4.55 and -12.41, Overvalued between -4.55 and -0.62, and Strongly Overvalued above -0.62. The current Forward P/OCF of -16.49 falls within the Strongly Undervalued range.
-13.37
P/FCF
Dianthus Therapeutics Inc. (DNTH) has a current P/FCF of -13.37. The 5-year average P/FCF is -7.18. The thresholds are as follows: Strongly Undervalued below -12.87, Undervalued between -12.87 and -10.02, Fairly Valued between -4.34 and -10.02, Overvalued between -4.34 and -1.49, and Strongly Overvalued above -1.49. The current Forward P/FCF of -13.37 falls within the Strongly Undervalued range.
Dianthus Therapeutics Inc (DNTH) has a current Price-to-Book (P/B) ratio of 3.45. Compared to its 3-year average P/B ratio of 1.96 , the current P/B ratio is approximately 75.70% higher. Relative to its 5-year average P/B ratio of 1.96, the current P/B ratio is about 75.70% higher. Dianthus Therapeutics Inc (DNTH) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -10.73%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -10.73% , the current FCF yield is about -100.00% lower.
3.51
P/B
Median3y
1.96
Median5y
1.96
-5.81
FCF Yield
Median3y
-10.73
Median5y
-10.73
Competitors Valuation Multiple
The average P/S ratio for DNTH's competitors is 0.00, providing a benchmark for relative valuation. Dianthus Therapeutics Inc Corp (DNTH) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -81.77%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of DNTH increased by 105.09% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.16K to -9.28K.
The secondary factor is the Revenue Growth, contributed -81.77%to the performance.
Overall, the performance of DNTH in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Dianthus Therapeutics Inc (DNTH) currently overvalued or undervalued?
What is Dianthus Therapeutics Inc (DNTH) fair value?
How does DNTH's valuation metrics compare to the industry average?
What is the current P/B ratio for Dianthus Therapeutics Inc (DNTH) as of Dec 05 2025?
What is the current FCF Yield for Dianthus Therapeutics Inc (DNTH) as of Dec 05 2025?
What is the current Forward P/E ratio for Dianthus Therapeutics Inc (DNTH) as of Dec 05 2025?